These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 3932097

  • 21. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction.
    Blumenfeld Z, Lang N, Amit A, Kahana L, Yoffe N.
    Fertil Steril; 1994 Sep; 62(3):456-60. PubMed ID: 8062938
    [Abstract] [Full Text] [Related]

  • 22. Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone in various ovulatory disorders.
    Saffan D, Seibel MM.
    Fertil Steril; 1986 Apr; 45(4):475-82. PubMed ID: 3082681
    [Abstract] [Full Text] [Related]

  • 23. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
    Sheehan KL, Casper RF, Yen SS.
    Am J Obstet Gynecol; 1979 Nov 15; 135(6):759-63. PubMed ID: 386801
    [Abstract] [Full Text] [Related]

  • 24. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A, Faure N.
    J Clin Endocrinol Metab; 1986 Dec 15; 63(6):1379-85. PubMed ID: 2946711
    [Abstract] [Full Text] [Related]

  • 25. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K, De Ziegler D, Cedars M, Meldrum DR, Lu JK, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1987 Oct 15; 65(4):773-8. PubMed ID: 3116031
    [Abstract] [Full Text] [Related]

  • 26. Induction of ovulation in the patient with polycystic ovarian disease.
    Blankstein J, Quigley MM.
    Endocrinol Metab Clin North Am; 1988 Dec 15; 17(4):733-49. PubMed ID: 3143566
    [Abstract] [Full Text] [Related]

  • 27. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE, Macchi M, Montanini V, Mongioi A, Maugeri G, Vicari E, Coniglione F, Sipione C, D'Agata R.
    J Clin Endocrinol Metab; 1987 May 15; 64(5):980-5. PubMed ID: 3104389
    [Abstract] [Full Text] [Related]

  • 28. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM, Randolph JF, Kelch RP, Marshall JC.
    J Clin Endocrinol Metab; 1991 Jun 15; 72(6):1278-85. PubMed ID: 1902845
    [Abstract] [Full Text] [Related]

  • 29. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan 15; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 30. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.
    Genazzani AD, Battaglia C, Gamba O, Petraglia F, Malavasi B, Genazzani AR.
    J Assist Reprod Genet; 2000 May 15; 17(5):269-75. PubMed ID: 10976414
    [Abstract] [Full Text] [Related]

  • 31. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE, Anania C, Malinak R.
    J Reprod Med; 1996 Sep 15; 41(9):645-52. PubMed ID: 8887188
    [Abstract] [Full Text] [Related]

  • 32. Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease: a new approach to induction of ovulation.
    Venturini PL, Remorgida V, Anserini P, De Cecco L.
    Gynecol Endocrinol; 1988 Sep 15; 2(3):205-13. PubMed ID: 3147583
    [Abstract] [Full Text] [Related]

  • 33. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE.
    J Clin Endocrinol Metab; 1996 Nov 15; 81(11):4103-7. PubMed ID: 8923867
    [Abstract] [Full Text] [Related]

  • 34. Ovulation induction with pulsatile luteinizing releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: clinical results.
    Burger CW, Korsen TJ, Hompes PG, van Kessel H, Schoemaker J.
    Fertil Steril; 1986 Dec 15; 46(6):1045-54. PubMed ID: 3096792
    [Abstract] [Full Text] [Related]

  • 35. The response of patients with polycystic ovarian disease to human menopausal gonadotropin therapy after ovarian electrocautery or a luteinizing hormone-releasing hormone agonist.
    Gadir AA, Alnaser HM, Mowafi RS, Shaw RW.
    Fertil Steril; 1992 Feb 15; 57(2):309-13. PubMed ID: 1735480
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
    Nillius SJ, Bergquist C, Wide L.
    Contraception; 1978 Jun 15; 17(6):537-45. PubMed ID: 352612
    [Abstract] [Full Text] [Related]

  • 37. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
    Timmerman-van Kessel EC, Cikot RJ, Dargel-Donkers EJ, Zwertbroek W, van Dop PA, Schoot DC.
    Fertil Steril; 2000 Jun 15; 73(6):1145-8. PubMed ID: 10856472
    [Abstract] [Full Text] [Related]

  • 38. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
    Leroy I, d'Acremont M, Brailly-Tabard S, Frydman R, de Mouzon J, Bouchard P.
    Fertil Steril; 1994 Sep 15; 62(3):461-7. PubMed ID: 8062939
    [Abstract] [Full Text] [Related]

  • 39. Selected aspects of polycystic ovarian disease.
    Goldzieher JW, Young RL.
    Endocrinol Metab Clin North Am; 1992 Mar 15; 21(1):141-71. PubMed ID: 1533584
    [Abstract] [Full Text] [Related]

  • 40. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD.
    J Clin Endocrinol Metab; 1991 Oct 15; 73(4):811-7. PubMed ID: 1909705
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.